These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25688500)

  • 1. Urinary modified nucleosides as novel biomarkers for diagnosis and prognostic monitoring of urothelial bladder cancer.
    Zhang YR; Shi L; Wu H; Tang DD; Wang SM; Liu HM; Zhang LR; Song DK
    Tumori; 2014; 100(6):660-6. PubMed ID: 25688500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Urine cytology and urine markers. Significance for clinical practice].
    Tritschler S; Zaak D; Knuechel R; Stief CG
    Urologe A; 2006 Nov; 45(11):W1441-7; quiz W1448. PubMed ID: 17063350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study.
    Couffignal C; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Mentre F; Cussenot O; Grandchamp B
    Urology; 2015 Dec; 86(6):1185-90. PubMed ID: 26364695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of urinary nucleosides in the diagnosis and surgical monitoring of colorectal cancer].
    Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Yu BM
    Zhonghua Wai Ke Za Zhi; 2005 May; 43(9):564-8. PubMed ID: 15938925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre and postoperative quantitative detection of fragments of cytokeratins 8 and 18 (UBC IRMA) as markers of early recurrence of superficial bladder tumor.
    Gacci M; Serni S; Lapini A; Giubilei G; Dal Canto M; Paladini S; Curotto A; Gallo F; Carmignani G; Carini M
    Arch Ital Urol Androl; 2006 Mar; 78(1):5-10. PubMed ID: 16752880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer.
    Witjes JA; van der Poel HG; van Balken MR; Debruyne FM; Schalken JA
    Eur Urol; 1998; 33(4):387-91. PubMed ID: 9612682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic role of survivin in urinary bladder cancer.
    Srivastava AK; Singh PK; Srivastava K; Singh D; Dalela D; Rath SK; Goel MM; Brahma Bhatt ML
    Asian Pac J Cancer Prev; 2013; 14(1):81-5. PubMed ID: 23534808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen.
    Ganas V; Kalaitzis C; Sountoulides P; Giannakopoulos S; Touloupidis S
    Minerva Urol Nefrol; 2012 Dec; 64(4):279-85. PubMed ID: 23288215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study.
    Kavalieris L; O'Sullivan P; Frampton C; Guilford P; Darling D; Jacobson E; Suttie J; Raman JD; Shariat SF; Lotan Y
    J Urol; 2017 Jun; 197(6):1419-1426. PubMed ID: 27986532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
    Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase activity in urine after transurethral resection is not a predictive marker for recurrence of superficial bladder cancer.
    Wu XX; Kakehi Y; Nishiyama H; Habuchi T; Ogawa O
    Int J Urol; 2003 Feb; 10(2):117-8. PubMed ID: 12588612
    [No Abstract]   [Full Text] [Related]  

  • 15. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients.
    Serretta V; Lo Presti D; Vasile P; Gange E; Esposito E; Menozzi I
    Urology; 1998 Nov; 52(5):793-6. PubMed ID: 9801101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma.
    Soukup V; Kalousová M; Capoun O; Sobotka R; Breyl Z; Pešl M; Zima T; Hanuš T
    Urol Int; 2015; 95(1):56-64. PubMed ID: 25662337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
    Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
    Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
    Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
    Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.
    Lokeshwar VB; Obek C; Pham HT; Wei D; Young MJ; Duncan RC; Soloway MS; Block NL
    J Urol; 2000 Jan; 163(1):348-56. PubMed ID: 10604388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
    Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
    Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.